Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery

  • PerioperativeIschemic Evaluation-2 Trial (POISE-2) Investigators
  • Cleveland Clinic Foundation
  • Population Health Research Institute, Ontario
  • McMaster University
  • University of Melbourne
  • Iberoamerican Cochrane Centre
  • University of Alberta
  • Universidad Autonoma de Bucaramanga
  • The University of Western Ontario
  • Narayana Health
  • Groote Schuur Hospital
  • Bispebjerg and Frederiksberg Hospital
  • Queen's University
  • St. John's Medical College and Research Institute
  • The Chinese University of Hong Kong
  • The University of North Carolina at Chapel Hill
  • University of Aberdeen
  • Medical University of Vienna
  • Shifa International Hospital
  • Universidad de los Andes, Chile
  • University of Malaya
  • España
  • Albert Einstein Hospital
  • University of Manitoba
  • Vita-Salute University
  • McMaster University, Faculty of Health Sciences

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

13 Citas (Scopus)

Resumen

Background: The authors previously reported that perioperative aspirin and/or clonidine does not prevent a composite of death or myocardial infarction 30 days after noncardiac surgery. Moreover, aspirin increased the risk of major bleeding and clonidine caused hypotension and bradycardia. Whether these complications produce harm at 1 yr remains unknown. Methods: The authors randomized 10,010 patients with or at risk of atherosclerosis and scheduled for noncardiac surgery in a 1:1:1:1 ratio to clonidine/aspirin, clonidine/aspirin placebo, clonidine placebo/aspirin, or clonidine placebo/aspirin placebo. Patients started taking aspirin or placebo just before surgery; those not previously taking aspirin continued daily for 30 days, and those taking aspirin previously continued for 7 days. Patients were also randomly assigned to receive clonidine or placebo just before surgery, with the study drug continued for 72 h. results: Neither aspirin nor clonidine had a significant effect on the primary 1-yr outcome, a composite of death or nonfatal myocardial infarction, with a 1-yr hazard ratio for aspirin of 1.00 (95% CI, 0.89 to 1.12; P = 0.948; 586 patients [11.8%] vs. 589 patients [11.8%]) and a hazard ratio for clonidine of 1.07 (95% CI, 0.96 to 1.20; P = 0.218; 608 patients [12.1%] vs. 567 patients [11.3%]), with effect on death or nonfatal infarction. Reduction in death and nonfatal myocardial infarction from aspirin in patients who previously had percutaneous coronary intervention at 30 days persisted at 1 yr. Specifically, the hazard ratio was 0.58 (95% CI, 0.35 to 0.95) in those with previous percutaneous coronary intervention and 1.03 (95% CI, 0.91to 1.16) in those without (interaction P = 0.033). There was no significant effect of either drug on death, cardiovascular complications, cancer, or chronic incisional pain at 1 yr (all P > 0.1). conclusions: Neither perioperative aspirin nor clonidine have significant long-term effects after noncardiac surgery. Perioperative aspirin in patients with previous percutaneous coronary intervention showed persistent benefit at 1 yr, a plausible sub-group effect.

Idioma originalInglés
Páginas (desde-hasta)692-701
Número de páginas10
PublicaciónAnesthesiology
Volumen132
N.º4
DOI
EstadoPublicada - 1 abr. 2020

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Citar esto